5-(8-氨基-7-氯-2,3-二氢-1,4-苯并二恶烷-5-基)-3-[1-(2-苯基乙基)哌啶-4-基]-1,3,4-恶二唑-2(3H)-酮盐酸盐 | 191023-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 5-(8-氨基-7-氯-2,3-二氢-1,4-苯并二恶烷-5-基)-3-[1-(2-苯基乙基)哌啶-4-基]-1,3,4-恶二唑-2(3H)-酮盐酸盐
• 英文名称: Capeserod hydrochloride
• 英文别名: 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one;hydrochloride
• CAS: 191023-43-5
• 化学式: C23H26Cl2N4O4
• 分子量: 493.4
• InChiKey: LNNFXZHLRNQJIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.81
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  benzyl N-[6-chloro-8-[5-oxo-4-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-yl]-2,3-dihydro-1,4-benzodioxin-5-yl]carbamate 生成 5-(8-氨基-7-氯-2,3-二氢-1,4-苯并二恶烷-5-基)-3-[1-(2-苯基乙基)哌啶-4-基]-1,3,4-恶二唑-2(3H)-酮盐酸盐
  参考文献：
  名称：

  5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for

  摘要：

  该一般式（I）的化合物 ##STR1## 其中R.sub.1代表（C.sub.1-C.sub.4）烷基或（C.sub.3-C.sub.7）环烷基甲基基团，X.sub.1代表氢或卤素原子或（C.sub.1-C.sub.4）烷氧基团或者OR.sub.1和X.sub.1一起代表公式- OCH.sub.2 O-，-O(CH.sub.2).sub.2-，-O(CH.sub.2).sub.3-，-O(CH.sub.2).sub.2O-或-O(CH.sub.2).sub.3O-的基团，X.sub.2代表氢原子或氨基团，X.sub.3代表氢或卤素原子，R.sub.2代表氢原子或可选取代的（C.sub.1-C.sub.6）烷基或苯（C.sub.1-C.sub.4）烷基基团，其在苯环上可选取代，或苯（C.sub.2-C.sub.3）烯基基团或苯氧（C.sub.2-C.sub.4）烷基基团或环（C.sub.3-C.sub.7）烷基甲基基团或2,3-二氢-1H-茚-1-基或2,3-二氢-1H-茚-2-基团或一般式-(CH.sub.2).sub.nCO-Z的基团，其中n代表1至6的数字，Z代表哌啶-1-基或4-（二甲氨基）哌啶-1-基团。应用于治疗学。

  公开号：

  US05929089A1

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：Verheijen C. Jeroen

  公开号：US20050096387A1

  公开（公告）日：2005-05-05

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

  碳酰基酯抑制胆碱酯酶活性，水解后释放出药理活性成分。在一种实施例中，碳酰基酯具有以下结构：其中A选自无取代芳基、取代芳基、无取代杂环芳基和取代杂环芳基的群组。碳酰基酯用于治疗个体的方法中。通过水解碳酰基酯获得的药理活性成分可以治疗例如神经系统疾病、胆碱能缺乏以及与药理活性成分缺乏相关的疾病或病症，例如乙酰胆碱。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation
  申请人：Braincells, Inc.

  公开号：EP2275095A2

  公开（公告）日：2011-01-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis via modulation of the muscarinic receptors
  申请人：Braincells, Inc.

  公开号：EP2275096A2

  公开（公告）日：2011-01-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。